FDA Renews IQOS Reduced-Risk Status, Fueling Public Health Debate

NEW DELHI – April 29, 2026 – The U.S. Food and Drug Administration has renewed its authorization for Philip Morris International's (PMI) IQOS heated tobacco system to be marketed as a “modified risk tobacco product” (MRTP), a decision that solidifies the product's unique standing in the U.S. market while intensifying the complex debate over tobacco harm reduction.

The renewal, announced this week, allows PMI to continue informing adult consumers that switching completely from conventional cigarettes to the IQOS system significantly reduces their body's exposure to a wide range of harmful chemicals. This regulatory green light is a significant victory for PMI's multi-billion-dollar strategy to shift smokers toward what it deems are safer alternatives, but it also reignites concerns among public health advocates about the potential for unintended consequences.

The FDA's Scientific Tightrope

At the core of the FDA's decision is a delicate public health calculation. The agency concluded that renewing the MRTP orders for the IQOS 2.4 and 3.0 devices, along with three HEETS tobacco consumable variants, is “appropriate to promote public health.”

In its order, the FDA reaffirmed its 2020 conclusion that, “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body's exposure to harmful or potentially harmful chemicals.” This finding is based on an extensive body of evidence submitted by PMI, which demonstrates that heating tobacco, rather than burning it, results in an aerosol with substantially lower levels of toxicants compared to cigarette smoke.

The agency's decision allows PMI to continue making specific, carefully worded “reduced exposure” claims. However, the FDA was quick to emphasize that the authorization does not mean the products are safe or “FDA approved.” The agency stressed that all tobacco products are harmful and that non-users, particularly youth, should not start using them. The renewal is contingent on continued post-market surveillance to monitor consumer understanding and behavior, especially among young people.

“As the only company to have successfully secured and maintained MRTP authorizations for heated tobacco products in the U.S., we are confident that our science-based alternatives can help adult smokers transition away from combustible cigarettes,” said Stacey Kennedy, CEO of PMI U.S., in a statement celebrating the decision.

A Calculated Bet for Public Health

The FDA's ruling underscores a deep and persistent rift within the public health community. On one side, proponents of harm reduction praise the decision as a pragmatic, science-based approach to a deadly problem. With approximately 25 million adults still smoking cigarettes in the U.S., they argue that providing access to less harmful, regulated alternatives is a crucial public health tool.

Advocates for this approach point to real-world data from markets like Japan, where the introduction of heated tobacco products has coincided with significant declines in cigarette sales. They argue that placing products like IQOS on a “continuum of risk” and communicating that difference to adult smokers is a responsible strategy. One commentator called the FDA's decision a “straightforward public health measure” that acknowledges the fundamental difference between combusted and non-combusted tobacco.

On the other side, many traditional tobacco control organizations remain deeply skeptical. Since IQOS first gained MRTP status, critics have argued that the decision sets a “dangerous precedent.” They express persistent fears that marketing a high-tech nicotine product with reduced-exposure claims could inadvertently appeal to youth, creating a new generation of nicotine users. These groups often highlight the tobacco industry's long history of using marketing to target young people and express concern that any new product could undermine decades of progress in tobacco control.

Concerns also persist about “dual use,” where smokers use both IQOS and conventional cigarettes, potentially negating any health benefits from reduced exposure. These organizations continue to advocate for stricter regulations, including flavor bans and higher taxes, on all nicotine products.

Fueling a Smoke-Free Transformation

For Philip Morris International, the FDA’s decision is more than just a regulatory victory; it’s a powerful endorsement of a corporate transformation more than a decade and $16 billion in the making. The company has staked its future on a pivot away from traditional cigarettes and toward a portfolio of “smoke-free” products.

This strategy is already paying significant financial dividends. Smoke-free products accounted for 41.5% of PMI’s total net revenues in 2025, a figure that rose to 43% in the first quarter of 2026. In many international markets, IQOS has already surpassed the iconic Marlboro brand in volume.

The MRTP reauthorization provides a crucial competitive advantage in the lucrative U.S. market. While competitors like British American Tobacco (BAT) and Japan Tobacco International (JTI) are also heavily investing in their own reduced-risk products like glo and Ploom, PMI is the only company that can legally market a heated tobacco product in the U.S. with claims of reduced chemical exposure. This regulatory moat is a key asset as the company, through its partner Altria, prepares for a broader national rollout following a temporary sales halt due to a patent dispute that ended in early 2025.

A New Landscape for Smokers and Regulators

For the millions of American smokers seeking alternatives, the FDA's decision means continued access to a product recognized as a less harmful option than cigarettes, at least in terms of chemical exposure. The reauthorization ensures that information about reduced exposure, vetted by a federal agency, can be part of the public conversation, empowering consumers to make more informed decisions about their health.

The regulatory landscape, however, remains complex. While the FDA has established a science-based pathway for reduced-risk products, many state and local governments continue to push for policies that treat all nicotine products identically. This creates a patchwork of regulations where a product federally authorized for its reduced-exposure characteristics may still face local flavor bans or be taxed at the same rate as combustible cigarettes.

Furthermore, the FDA’s decision on IQOS sets a precedent for other novel nicotine products. Swedish Match, now owned by PMI, is currently seeking MRTP status for its ZYN nicotine pouches. How the FDA handles this and other future applications will shape the future of nicotine regulation in the U.S. for years to come. The ongoing tension between federal harm reduction efforts and local public health concerns ensures that while the science may be settling on some fronts, the debate over the future of tobacco is far from over.